Evidence map›Paper›PMID 41287048›Full record

ArticleTrials2025

Effects of personalized live-remote exercise for individuals living beyond primary curative cancer treatment: study protocol for a multinational, super umbrella randomized controlled trial (LION-RCT).

Anouk E Hiensch, Jana Müller, Eva M Zopf, Martina E Schmidt, Evelyn M Monninkhof, Mark Trevaskis, Jon Belloso, Dorothea Clauss, Nadira Gunasekara, Ana Joaquim and 19 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06270628 (Demonstrating the), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06270628 narecruitingnot on this map

Demonstrating the (Cost-)Effectiveness of a Personalized Live-remote Exercise Intervention for Cancer Survivors Using a Super Umbrella Randomized Controlled Trial: the LION RCT

TypeinterventionalSponsorUMC UtrechtRan2024 to 2027Enrolled350ConditionsNeoplasmsArmsExercise group
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Anouk E Hiensch *Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, GA, 3508, The Netherlands.
Jana Müller *Department of Medical Oncology, Exercise Oncology Research Group, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, National Center for Tumor Diseases Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
Eva M Zopf *Cabrini Cancer Institute, Cabrini Health, Melbourne, VIC, Australia.
Martina E Schmidt *Division of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany.
Evelyn M Monninkhof *Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, GA, 3508, The Netherlands.
Mark TrevaskisMary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia.
Jon BellosoGipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
Dorothea ClaussDivision of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany.
Nadira GunasekaraInstitute for Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.
Ana JoaquimONCOMOVE®-Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Vila Nova Gaia, Portugal.
Sofia ViamonteONCOMOVE®-Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Vila Nova Gaia, Portugal.
Moritz SchumannDepartment of Sports Medicine and Exercise Therapy, Chemnitz University of Technology, Chemnitz, Germany.
Lars HeinrichInstitute for Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.
Alina KiasDivision of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany.
David BinyamJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, GA, 3508, The Netherlands.
Lonneke van de PollDepartment of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Laurien M BuffartDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Neil K AaronsonDepartment of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Elsken van der WallJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, GA, 3508, The Netherlands.
Anna CampbellSchool of Applied Science, Edinburgh Napier University, Edinburgh, Scotland, UK.
Joachim WiskemannDepartment of Medical Oncology, Exercise Oncology Research Group, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, National Center for Tumor Diseases Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
Helene RundqvistKarolinska Institutet and Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Alberto J AlvesONCOMOVE®-Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Vila Nova Gaia, Portugal.
Ander UrruticoecheaGipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
Wilhelm BlochInstitute for Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.
Martijn M StuiverDepartment of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Yvonne WengströmKarolinska Institutet and Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Karen Steindorf *Division of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany.
Anne M May *Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, GA, 3508, The Netherlands. a.m.may@umcutrecht.nl.

Funding

Horizon Europe Research and Innovation Programme 101057059National Health and Medical Research Council of the Australian Government 2017666
6 · The paper itself

Abstract

backgroundExercise is an effective strategy to reduce cancer- and treatment-related side effects and improve quality of life (QoL). Larger exercise effects are observed in cancer survivors with a higher symptom burden and when exercise interventions are supervised. Most studies conducted to date have not screened for symptoms at baseline and tailored the exercise intervention accordingly. Additionally, time and travel distance are common barriers to participation in supervised in-person exercise programs. Live-remote exercise, where exercise sessions are supervised by an exercise professional via a videoconferencing platform, might help overcome these barriers. Here, we describe the design of the LION randomized controlled trial (RCT). This RCT aims to assess the (cost-)effectiveness of side effect-targeted, live-remote exercise on QoL and the participants' most burdensome side effect-fatigue, emotional distress, low physical functioning, or chemotherapy-induced peripheral neuropathy (CIPN)-in individuals who have completed primary curative cancer treatment.

methodsThe LION study is a multinational RCT that will enroll 352 individuals who have completed primary curative cancer treatment including chemotherapy, within the previous 12-52 weeks and screen positive for ≥ 1 of the targeted side effects. Participants are randomly allocated (1:1) to the intervention or wait list control group. Participants in the intervention group receive a 12-week supervised exercise program consisting of three live-remote exercise sessions per week. Each participant receives the same base module (2×/week) and one specific module (1×/week) targeting their most burdensome side effect. Wait list control participants receive the same exercise program 12 weeks post-baseline. The primary outcomes are HRQoL (EORTC QLQ-C30 summary score) and a standardized symptom score based on each participant's most burdensome side effect (physical fatigue: EORTC QLQ-FA12, emotional distress: PHQ-ADS, physical functioning: EORTC QLQ-C30 modified physical functioning scale, CIPN: EORTC QLQ-CIPN20), assessed at baseline, 6, 12 (primary time point), 18 (wait list control group only), 24 and 36 weeks post-baseline. DISCUSSION: This RCT will provide evidence regarding the (cost-)effectiveness of side effect-targeted, live-remote exercise in individuals experiencing side effects following primary curative cancer treatment. If proven (cost-)effective, live-remote exercise could be offered to individuals as part of standard follow-up cancer care to extend the reach of exercise support.

trial registrationNCT06270628. Registered on February 13, 2024.

Indexed as

Cancer SurvivorsExercise TherapyNeoplasmsVideoconferencingAntineoplastic AgentsCost-Benefit AnalysisFemaleHumansMaleMulticenter Studies as TopicPsychological DistressQuality of LifeRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeAntineoplastic AgentsCancerEmotional distressExerciseFatigueOnline live-remotePeripheral neuropathyPhysical functioningQuality of lifeRandomized controlled trial

Identifiers

PMID41287048
PMCPMC12642165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.